What is telogen effluvium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Telogen Effluvium?

Telogen effluvium (TE) is a common form of diffuse, non-scarring hair loss caused by an increased proportion of hair follicles prematurely entering the telogen (resting) phase, resulting in excessive shedding of normal club hairs typically 2-3 months after a triggering stressor. 1, 2

Pathophysiology

TE represents a disruption of the normal hair cycle where physiological or psychological stress causes hair follicles to prematurely terminate the anagen (growth) phase and shift into telogen 3. The condition manifests as increased loss of telogen club hairs, though the exact mechanisms through which stress influences the human hair cycle remain incompletely understood 4.

Five distinct functional mechanisms have been proposed 5:

  • Immediate anagen release - abrupt termination of growth phase
  • Delayed anagen release - gradual shortening of growth phase
  • Short anagen syndrome - constitutionally shortened growth phase
  • Immediate telogen release - premature shedding of resting hairs
  • Delayed telogen release - prolonged retention followed by synchronized shedding

Recent evidence suggests that anagen shortening precedes follicular miniaturization, establishing TE as a potential precursor to androgenetic alopecia in men 6. This challenges traditional thinking about the relationship between these conditions.

Common Triggers

TE is multifactorial with numerous precipitants 1:

  • Medical/surgical stressors - childbirth, prolonged surgery, severe febrile illness
  • Rapid weight loss - mean threshold approximately 15% body weight loss at 3.54 kg/month 7
  • Medications - chemotherapy and various other drugs
  • Nutritional deficiencies - though less common than traditionally believed 8
  • Endocrine disorders - thyroid dysfunction
  • Psychological stress - though the bidirectional relationship between stress and hair loss creates diagnostic complexity 9

Clinical Presentation

The hallmark is diffuse hair shedding across the entire scalp rather than patterned loss 10, 4. Patients typically present with significant anxiety about sudden excessive hair loss, which substantially impacts quality of life even though the condition is generally self-limited 10, 9.

Critical timing: Hair loss becomes clinically apparent 2-3 months after the triggering event, reflecting the normal telogen duration before shedding occurs.

Diagnostic Approach

Diagnosis requires three key elements:

  1. Hair pull test - positive with easy extraction of telogen hairs
  2. Dermoscopic examination - to exclude other causes of diffuse hair loss
  3. Detailed history - to identify temporal relationship with known triggers occurring 2-3 months prior 10

Important caveat: The diagnosis is based on an increased telogen:anagen ratio, NOT on patient-reported quantity of shedding 6. In men with short hair, TE may go completely unnoticed despite being present.

Laboratory Evaluation

Contrary to popular belief, nutritional deficiencies are not as common as traditionally thought in TE patients 8. However, when investigating persistent cases, consider:

  • Zinc levels (significantly lower in chronic TE) 8
  • Ferritin and hemoglobin
  • Thyroid function tests
  • Vitamin B12 and vitamin D
  • Copper/zinc ratio (elevated in TE) 8

Do not routinely order comprehensive nutritional panels - instead, use targeted testing based on specific clinical suspicion from the history 8.

Prognosis and Impact

TE is generally self-limited with high remission rates 4. However, the psychological impact is substantial - patients with TE demonstrate significantly higher scores for depression, anxiety, perceived stress, and reduced quality of life compared to controls 9. These psychological effects correlate directly with the degree of quality of life impairment.

Treatment Considerations

Minoxidil (topical or low-dose oral) is the primary treatment for TE 2. The medication works by:

  • Prolonging anagen phase
  • Promoting telogen-to-anagen transition
  • Transforming vellus hairs to terminal hairs

For diffuse scalp involvement, low-dose oral minoxidil is preferred over topical formulations due to ease of use and patient compliance 2.

Key Clinical Pitfalls

  • Do not dismiss TE as a "waste basket diagnosis" - it requires proper confirmation through hair pull testing and dermoscopy 11
  • Failure to observe shedding does not negate TE diagnosis - particularly in men with short hair 6
  • Do not assume nutritional deficiency without evidence - create individualized treatment plans based on identified triggers rather than empiric supplementation 8
  • Recognize the bidirectional stress-hair loss relationship - address both the physical trigger and psychological impact 9

References

Research

Telogen effluvium.

Clinical and experimental dermatology, 2002

Research

Telogen Effluvium - a review of the science and current obstacles.

Journal of dermatological science, 2021

Research

Telogen effluvium. New concepts and review.

Archives of dermatology, 1993

Research

Telogen effluvium: a 360 degree review.

Italian journal of dermatology and venereology, 2023

Research

Telogen effluvium.

Indian journal of dermatology, venereology and leprology, 2013

Related Questions

What are the causes, evaluation, and management of hair loss (telogen effluvium) during pregnancy?
What is telogen effluvium and why does it cause increased shedding during the telogen phase?
Should Nutrafol be used to treat telogen effluvium, and what is the recommended regimen?
In a 40-year-old man with diffuse uniform scalp hair thinning and shedding of large hair clumps after a cholecystectomy four months ago, no medication use and a normal physical examination, what is the most appropriate next step and management?
With a lithium serum concentration of 0.8 mEq/L, is it possible to have no hair‑related side effects such as hair loss (telogen effluvium) and dandruff?
In a 5‑month‑old infant with bronchiolitis, is treatment with nebulized salbutamol and ipratropium bromide appropriate?
In a patient with chronic irritable bowel syndrome presenting with periumbilical cramping 2–3 hours after meals and no alarm features, could this be a duodenal ulcer?
What is the treatment for pleural effusion in a patient with renal insufficiency?
In a patient with nocturnal epigastric pain that does not wake them but becomes severe upon awakening with hunger, what is the appropriate diagnostic and therapeutic approach?
In a 71-year-old woman with hypertension and end-stage renal disease (chronic kidney disease stage V) who has episodic hypotension, somnolence, and confusion, what are the possible diagnoses?
In a patient with H. pylori‑negative epigastric pain syndrome (functional dyspepsia) who also has irritable bowel syndrome, what is the recommended management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.